Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220854 · ClinicalTrials.gov registry record · Phase 2
SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx
A Phase 2 study of Solid Tumor, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT03220854 is a Phase 2 study of Solid Tumor that has completed, run by Virginia Commonwealth University. The registered enrollment target is 5 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03220854, a Phase 2 study of Solid Tumor, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if having radiation therapy and continuing immunotherapy can improve the benefit of immunotherapy. There have been reports of patients who were treated with radiation therapy that not only caused the treated tumors to shrink or stop growing, but also resulted in tumors that had not been treated in other parts of the body to shrink or stop growing. This effect is thought to be brought about by cells in the body's immune system that become active as a result of the effects of radiation therapy. If radiation therapy can stimulate the immune system, it may be possible for immunotherapy to be helpful again in treating a cancer that the immunotherapy drug helped treat before. This study will also check if receiving immunotherapy at the end of radiation therapy has any effect on the side effects of radiation therapy or immunotherapy.
Conditions Studied
Interventions
- RADIATION Stereotactic radiotherapy
- OTHER Biological: humanized anti-PD-1 monoclonal antibody
- OTHER Biological: humanized anti-PD-L1 monoclonal antibody
Study Locations (1)
Virginia
- Virginia Commonwealth University/Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-10-10 |
| Est. Completion | 2021-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03220854
The ClinicalTrials.gov registry entry for NCT03220854 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (98% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Stereotactic radiotherapy is the first listed.
NCT03220854 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT03220854 about?
NCT03220854 is a clinical study titled "SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx". The purpose of this study is to find out if having radiation therapy and continuing immunotherapy can improve the benefit of immunotherapy. There have been reports of patients who were treated with radiation therapy that not only caused the treated tumors to shrink or stop growing, but also resulted...
What is the current status of trial NCT03220854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-10-10. Estimated completion is 2021-09-22.
What conditions does trial NCT03220854 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT03220854?
The interventions under investigation include: Stereotactic radiotherapy (RADIATION), Biological: humanized anti-PD-1 monoclonal antibody (OTHER), Biological: humanized anti-PD-L1 monoclonal antibody (OTHER).
Who is sponsoring clinical trial NCT03220854?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03220854 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.